Europe Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe) Forecasts, 2026-2034

Europe Cell and Gene Therapy Manufacturing QC Market Size

The Europe Cell and Gene Therapy Manufacturing QC Market size was valued at USD 0.80 billion in 2025 and is projected to grow from USD 0.95 billion in 2026 to USD 3.65 billion by 2034 at a CAGR of 18.37% during the forecast period 2026–2034.

The European cell and gene therapy manufacturing quality control (QC) market has gained significant traction in recent years, driven by advancements in biotechnology and the growing demand for personalized medicine. Moreover, the surge in the trend of outsourcing QC services from prominent biotechnology companies is estimated to create opportunities for global cell and gene therapy manufacturing qa market expansion.

Workflow Insights

Vector Production dominates the workflow segment and is expected to augment at a CAGR of 26.8%. The vector production workflow segment is expanding rapidly as viral vectors are crucial for delivering genetic material in gene therapies. With the growing number of gene therapy applications, especially for rare diseases and cancer, the need for high-quality, scalable vector production is rising. Advances in viral vector design and manufacturing technologies are further boosting this segment's growth.

Request Customizationto receive a tailored report.

Process Insights

Upstream Processes dominates the process segment and is estimated to grow at a CAGR of 25.5%. The upstream processes segment is witnessing growth due to the increasing demand for advanced bioprocessing technologies. These processes, including cell culture, viral vector production, and gene editing, are crucial for scaling production. Technological innovations in bioreactors and automation are enhancing the efficiency and reliability of upstream processes.

End User Insights

Biopharmaceutical/biotechnological companies are estimated to own the end-user segment and are anticipated to expand at a CAGR of 25.4%. Biopharmaceutical and biotechnological companies are driving regional industry growth due to their significant investment in personalized medicine and advanced therapies. With increasing clinical trials and regulatory approvals for cell and gene therapies, these companies require stringent quality control measures, fueling demand for specialized QC technologies to ensure safety and compliance.

Speak to an Analystto discuss market opportunities.

Country Insights

The European market for cell and gene therapy manufacturing QC is highly concentrated in Western Europe, particularly in countries like Germany, the UK, and France. Germany, as the largest biotechnology hub in Europe, holds the largest share, driven by strong government support, advanced research infrastructure, and a robust pharmaceutical industry. The country's extensive R&D ecosystem, backed by initiatives like the "German Biotech Industry Strategy 2025," emphasizes the development of cutting-edge bioprocessing technologies, including QC testing.

In the UK, initiatives like the Cell and Gene Therapy Catapult, which focuses on accelerating innovation and commercialization in the sector, play a key role in market expansion. France is also witnessing growth due to its government's investment in research for this field, along with the presence of large biopharma companies such as Sanofi. Furthermore, Eastern Europe, while still emerging in the biotech space, is gradually gaining traction, with countries like Poland and Hungary investing in research and clinical trials, offering future growth potential for the QC market in cell and gene therapy manufacturing.

List of Key and Emerging Players in Europe Cell and Gene Therapy Manufacturing QC Market